Posted by Michael Wonder on 17 Jun 2022
Outcomes of the May 2022 PBAC intracycle meeting
17 June 2022 - The outcomes from the May 2022 PBAC meeting are now available.
The PBAC considered the following medicines:
- Apremilast
- Armodafinil
- Burosumab
- Daratumumab with hyaluronidase
- Dulaglutide
- Faricimab
- Modafinil
- Pembrolizimab
- Pregabalin
- Trientine dihydrochloride
- Trientine tetrahydrochloride
